A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving Durvalumab

AstraZeneca144 enrolled

Overview

Objective in this study is to investigate feasibility of developing machine-learning based model for the identification of future development of diagnosed Grade 2 and higher ILD and of disease progression in patients with unresectable Stage III NSCLC receiving durvalumab

Study design: Multicentre, prospective, non-interventional pilot study Data Source(s): Medical records, wearable devices, and mobile application. Study Population:Patients treated durvalumab following chemoradiation therapy for stage III unresectable NSCLC in Japan from the June 2021 to June 2022. They must fulfil all of the inclusion /exclusion criteria. Exposure(s): dulvalumab Outcome(s): Disease progression, ILD including radiation pneumonitis. Sample Size Estimations : 150 patients Statistical Analysis: Continuous variables will be reported as mean, median, standard deviation, IQR, maximum, and minimum. Categorical variables will be summarized as absolute frequency and percentage. Ninety-five percent confidence intervals (CIs) will be presented where appropriate. Time-to event for ILD/Disease progression will be estimated by Kaplan-Meir method. Also, in the process of developing model, data production such as per-patient plots of the physiological data(multivariate time series) and physiological data before and after (in a shorter time-scale) the ILD event per event will be considered.

Study Type

OBSERVATIONAL

Enrollment

144

Conditions

Carcinoma, Non-Small-Cell Lung

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient who provided written signed informed consent prior to the first study-specific procedures. * Patient who receives durvalumab for unresectable stage III NSCLC at first time following chemoradiation therapy * Patient whose performance status showed 0 or 1 prior to durvalumab treatment * Patient who is able and willing to wear the devices daily for up to 6 months as instructed Exclusion Criteria: * Patient under immunotherapy treatment other than durvalumab. * Patient had received prior immunotherapy * Patient under the interventional clinical studies using unapproved drugs or off-label use of drugs * Patient who showed ILD (including radiation pneumonitis) of Grade 2 and higher, after consolidated chemoradiation therapy. * Patient who is judged as not suitable for the study by the study site investigators, in terms of fitting wearable devices, presence of silicone or metallic allergy

Locations (27)

Research Site

Nagoya, Aichi-ken, Japan

Outcomes

Primary Outcomes

Grade 2 and higher ILD including radiation pneumonitis

Time frame: 6 months

Secondary Outcomes

Disease progression

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.